Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

[1]  W. Regine,et al.  Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. , 2011, International journal of radiation oncology, biology, physics.

[2]  J. Cameron,et al.  A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. , 2010, Translational oncology.

[3]  Jeff Myers,et al.  Interconversion of three measures of performance status: an empirical analysis. , 2010, European journal of cancer.

[4]  Walter G. Park,et al.  EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. , 2010, Gastrointestinal endoscopy.

[5]  Eric C Ford,et al.  Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. , 2010, International journal of radiation oncology, biology, physics.

[6]  Ellen Yorke,et al.  18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy* , 2009, Journal of Nuclear Medicine.

[7]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[8]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Chung-Pin Li,et al.  Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. , 2009, International journal of radiation oncology, biology, physics.

[10]  T. Desser,et al.  Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.

[11]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Friess,et al.  Final results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine , 2008 .

[14]  A. Benson,et al.  A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 , 2008 .

[15]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[16]  Edgar Ben-Josef,et al.  Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[17]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Quynh-Thu Le,et al.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[19]  Jeffrey W. Clark,et al.  Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer , 2005, Annals of surgery.

[20]  Jay Burmeister,et al.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[21]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[22]  B. Jeremic,et al.  Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy , 2003, Journal of Cancer Research and Clinical Oncology.

[23]  H. Ueno,et al.  Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy , 2001, Cancer.

[24]  J. Vauthey,et al.  Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer , 2001, International journal of gastrointestinal cancer.

[25]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Lawrence,et al.  Gemcitabine-mediated radiosensitization. , 1997, Seminars in oncology.

[27]  K. Aoki,et al.  Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy , 1996, Pancreas.

[28]  C. Haglund,et al.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. , 1994, British Journal of Cancer.

[29]  S A Leibel,et al.  The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. , 1991, International journal of radiation oncology, biology, physics.

[30]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.

[31]  P. Engstrom,et al.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Pajak,et al.  Multimodality therapy of localized unresectable pancreatic adenocarcinoma , 1984, Cancer.

[33]  J. Barkin,et al.  Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group , 1981, Cancer.